Business Wire1mon
Aulos Bioscience Presents Phase 2 Dose Selection Data for Novel IL-2 Therapeutic Antibody, AU-007, at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today ...
Business Wire7d
Aulos Bioscience Doses First Patient in Phase 2 Cohort Evaluating the Combination of Avelumab and AU-007 for the Treatment of Non-Small Cell Lung Cancer
LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today ...
GlobalData on MSN7d
Aulos Bioscience doses first patient in avelumab lung cancer trial
US-based immuno-oncology company Aulos Bioscience has announced the first patients have been dosed as part of a trial ...
Yahoo Finance7d
Aulos Bioscience doses first patient in avelumab lung cancer trial
US-based immuno-oncology company Aulos Bioscience has announced the first patients have been dosed as part of a trial investigating avelumab, marketed as Bavencio by its original developer Merck ...